FDA NDA · NDA019715
DIPENTUM
olsalazine sodium
Sponsor: MYLAN SPCLT VIATRIS
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
NDA019715
TYPE
NDA
ORIGINAL APPROVAL
1990-07-31
LATEST ACTION
2026-10-14
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
DIPENTUM · ReferencePrescription
OLSALAZINE SODIUM 250MG · CAPSULE · ORAL
Approval history
2002-11-12Manufacturing (CMC) · Supplement 22 · priorityAP
2001-02-14Manufacturing (CMC) · Supplement 20 · priorityAP
2000-09-08Labeling · Supplement 19 · standardAP
1999-06-30Labeling · Supplement 17 · standardAP
1996-09-11Manufacturing (CMC) · Supplement 15 · priorityAP
1996-06-12Manufacturing (CMC) · Supplement 11 · priorityAP
1996-06-06Manufacturing (CMC) · Supplement 16 · priorityAP
1996-06-04Manufacturing (CMC) · Supplement 9 · priorityAP
1996-01-31Manufacturing (CMC) · Supplement 12 · priorityAP
1996-01-29Manufacturing (CMC) · Supplement 14 · priorityAP
1995-03-23Manufacturing (CMC) · Supplement 10 · priorityAP
1995-02-08Labeling · Supplement 13 · standardAP
1995-01-26Manufacturing (CMC) · Supplement 4 · priorityAP
1994-09-22Manufacturing (CMC) · Supplement 8 · priorityAP
1994-05-26Manufacturing (CMC) · Supplement 7 · priorityAP
1994-05-24Manufacturing (CMC) · Supplement 6 · priorityAP
1993-12-08Labeling · Supplement 5 · standardAP
1993-08-09Manufacturing (CMC) · Supplement 1 · priorityAP
1993-03-15Labeling · Supplement 3 · standardAP
1993-01-05Labeling · Supplement 2 · standardAP
1990-07-31Type 1 - New Molecular Entity · Original · priorityAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →